Genmab A/S (GMAB) vs Eli Lilly and Company (LLY)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| GMAB | LLY | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Size band | LARGE | MEGA |
| Listing | Nasdaq GS | NYSE |
| Country | Denmark | United States |
| Theme | oncology | glp-1-and-obesity |
| Price and returns | ||
| Last close | $44.69 | $1,279.14 |
| Return · 1 week | +16.06% | +3.13% |
| Return · 1 month | +26.37% | +7.96% |
| Return · 3 months | +54.09% | +4.79% |
| Return · year to date | +40.43% | +18.80% |
| Return · 1 year | +53.93% | +55.54% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −1.67% | −3.18% |
| 52-week high | $45.45 | $1,321.21 |
| 52-week low | $23.62 | $793.82 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $27.48B | $1.14T |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $123.02M | $2.81B |
| Employees | 3,119 | 50,000 |
| Valuation | ||
| Price to earnings · trailing | 29.13× | 42.75× |
| Price to earnings · forward | 24.42× | 26.97× |
| Price to sales | 5.51× | 14.25× |
| Price to book | 3.71× | 33.51× |
| Enterprise value to EBITDA | 18.78× | 28.32× |
| Enterprise value to revenue | 6.26× | 14.83× |
| PEG ratio | 4.64 | 1.23 |
| Earnings per share · trailing | 1.27 | 29.79 |
| Profitability | ||
| Gross margin | 93.03% | 83.40% |
| Operating margin | 35.24% | 54.22% |
| Profit margin | 19.08% | 33.53% |
| Return on equity | 14.00% | 102.29% |
| Return on assets | 8.79% | 20.36% |
| Growth | ||
| Revenue growth | +24.90% | +47.70% |
| Earnings growth | −9.40% | +26.20% |
| Balance sheet and payout | ||
| Debt / equity (%) | 88.52 | 162.07 |
| Current ratio | 2.46 | 1.36 |
| Dividend yield | 0.00% | 0.54% |
| Payout ratio | 0.00% | 21.69% |
| Trend and volatility | ||
| RSI · 14 | 79.57 | 63.04 |
| ADX · 14 | 35.54 | 31.31 |
| 50-day average | $35.47 | $1,188.58 |
| 200-day average | $30.11 | $1,085.91 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.31% | 3.16% |
The full GMAB analysis
Everything this table leaves out for Genmab A/S: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GMAB argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GMAB analysisThe full LLY analysis
Everything this table leaves out for Eli Lilly and Company: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the LLY argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full LLY analysis